Cargando…

First 2 Fabry Cases with Novel Mutation and Their Associated Clusters in Malaysia

Case series Patients: Male, 39-year-old (age at diagnosis) • Male, 62-year-old (age at diagnosis) Final Diagnosis: Fabry disease Symptoms: Corneal verticillata • kidney failure • neuropathy • proteinuria Medication: — Clinical Procedure: — Specialty: Genetics • Hematology • Laboratory Diagnostics •...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Andy Sing Ong, Wong, Qi Ying, Ting, Ingrid Pao Lin, Selvesten, Panting, Yeo, Siaw Tze, Chew, Lee Ping, Fam, Tem Lom, Tan, Clare Hui Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351246/
https://www.ncbi.nlm.nih.gov/pubmed/34354036
http://dx.doi.org/10.12659/AJCR.932923
_version_ 1783735932834283520
author Tang, Andy Sing Ong
Wong, Qi Ying
Ting, Ingrid Pao Lin
Selvesten, Panting
Yeo, Siaw Tze
Chew, Lee Ping
Fam, Tem Lom
Tan, Clare Hui Hong
author_facet Tang, Andy Sing Ong
Wong, Qi Ying
Ting, Ingrid Pao Lin
Selvesten, Panting
Yeo, Siaw Tze
Chew, Lee Ping
Fam, Tem Lom
Tan, Clare Hui Hong
author_sort Tang, Andy Sing Ong
collection PubMed
description Case series Patients: Male, 39-year-old (age at diagnosis) • Male, 62-year-old (age at diagnosis) Final Diagnosis: Fabry disease Symptoms: Corneal verticillata • kidney failure • neuropathy • proteinuria Medication: — Clinical Procedure: — Specialty: Genetics • Hematology • Laboratory Diagnostics • Nephrology • Neurology • Ophthalmology OBJECTIVE: Rare disease BACKGROUND: No cases of Fabry disease (FD) have been reported thus far in Malaysia. We aimed to report the demographic characteristics, clinical manifestations, molecular results, and treatment outcomes of 2 FD cases. This study was a retrospective review of 2 family clusters of FD on follow-up in Sarawak, Malaysia. CASE REPORTS: Two index patients were confirmed to have FD. Index patient 1, who had nephrotic-range proteinuria and cornea verticillata, carried a variant within exon 4 of the GLA gene: c.610 T>C (p.Trp204Arg). Agalsidase beta (Fabrazyme(®)) enzyme replacement therapy was initiated, with the absence of neutralizing antibody after 24 months. No hypersensitivity or adverse reactions were reported. The patient’s proteinuria and renal function remained stable. Other family members who carried the same mutation were asymptomatic. Index patient 2, who had residual activity of α-galactosidase A and a normal globotriaosylsphingosine level, carried a novel GLA mutation of c.548-5T>A. He was diagnosed with end-stage renal disease on regular dialysis and had nonspecific headache with 1 episode of seizure a few years prior to FD genetic screening. One brother had chronic neuropathic pain but refused further investigations. Other family members who had the same mutation were asymptomatic. This mutation has never been reported in literature, and its pathogenicity warrants further studies. CONCLUSIONS: It is of utmost importance to increase awareness of FD among clinicians, so that appropriate screening may be done to determine its true prevalence and prompt treatment can be initiated early.
format Online
Article
Text
id pubmed-8351246
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher International Scientific Literature, Inc.
record_format MEDLINE/PubMed
spelling pubmed-83512462021-08-23 First 2 Fabry Cases with Novel Mutation and Their Associated Clusters in Malaysia Tang, Andy Sing Ong Wong, Qi Ying Ting, Ingrid Pao Lin Selvesten, Panting Yeo, Siaw Tze Chew, Lee Ping Fam, Tem Lom Tan, Clare Hui Hong Am J Case Rep Articles Case series Patients: Male, 39-year-old (age at diagnosis) • Male, 62-year-old (age at diagnosis) Final Diagnosis: Fabry disease Symptoms: Corneal verticillata • kidney failure • neuropathy • proteinuria Medication: — Clinical Procedure: — Specialty: Genetics • Hematology • Laboratory Diagnostics • Nephrology • Neurology • Ophthalmology OBJECTIVE: Rare disease BACKGROUND: No cases of Fabry disease (FD) have been reported thus far in Malaysia. We aimed to report the demographic characteristics, clinical manifestations, molecular results, and treatment outcomes of 2 FD cases. This study was a retrospective review of 2 family clusters of FD on follow-up in Sarawak, Malaysia. CASE REPORTS: Two index patients were confirmed to have FD. Index patient 1, who had nephrotic-range proteinuria and cornea verticillata, carried a variant within exon 4 of the GLA gene: c.610 T>C (p.Trp204Arg). Agalsidase beta (Fabrazyme(®)) enzyme replacement therapy was initiated, with the absence of neutralizing antibody after 24 months. No hypersensitivity or adverse reactions were reported. The patient’s proteinuria and renal function remained stable. Other family members who carried the same mutation were asymptomatic. Index patient 2, who had residual activity of α-galactosidase A and a normal globotriaosylsphingosine level, carried a novel GLA mutation of c.548-5T>A. He was diagnosed with end-stage renal disease on regular dialysis and had nonspecific headache with 1 episode of seizure a few years prior to FD genetic screening. One brother had chronic neuropathic pain but refused further investigations. Other family members who had the same mutation were asymptomatic. This mutation has never been reported in literature, and its pathogenicity warrants further studies. CONCLUSIONS: It is of utmost importance to increase awareness of FD among clinicians, so that appropriate screening may be done to determine its true prevalence and prompt treatment can be initiated early. International Scientific Literature, Inc. 2021-06-08 /pmc/articles/PMC8351246/ /pubmed/34354036 http://dx.doi.org/10.12659/AJCR.932923 Text en © Am J Case Rep, 2021 https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) )
spellingShingle Articles
Tang, Andy Sing Ong
Wong, Qi Ying
Ting, Ingrid Pao Lin
Selvesten, Panting
Yeo, Siaw Tze
Chew, Lee Ping
Fam, Tem Lom
Tan, Clare Hui Hong
First 2 Fabry Cases with Novel Mutation and Their Associated Clusters in Malaysia
title First 2 Fabry Cases with Novel Mutation and Their Associated Clusters in Malaysia
title_full First 2 Fabry Cases with Novel Mutation and Their Associated Clusters in Malaysia
title_fullStr First 2 Fabry Cases with Novel Mutation and Their Associated Clusters in Malaysia
title_full_unstemmed First 2 Fabry Cases with Novel Mutation and Their Associated Clusters in Malaysia
title_short First 2 Fabry Cases with Novel Mutation and Their Associated Clusters in Malaysia
title_sort first 2 fabry cases with novel mutation and their associated clusters in malaysia
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351246/
https://www.ncbi.nlm.nih.gov/pubmed/34354036
http://dx.doi.org/10.12659/AJCR.932923
work_keys_str_mv AT tangandysingong first2fabrycaseswithnovelmutationandtheirassociatedclustersinmalaysia
AT wongqiying first2fabrycaseswithnovelmutationandtheirassociatedclustersinmalaysia
AT tingingridpaolin first2fabrycaseswithnovelmutationandtheirassociatedclustersinmalaysia
AT selvestenpanting first2fabrycaseswithnovelmutationandtheirassociatedclustersinmalaysia
AT yeosiawtze first2fabrycaseswithnovelmutationandtheirassociatedclustersinmalaysia
AT chewleeping first2fabrycaseswithnovelmutationandtheirassociatedclustersinmalaysia
AT famtemlom first2fabrycaseswithnovelmutationandtheirassociatedclustersinmalaysia
AT tanclarehuihong first2fabrycaseswithnovelmutationandtheirassociatedclustersinmalaysia